Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM. Subbiah V, et al. Oncology. 2016;91(6):348-353. doi: 10.1159/000449204. Epub 2016 Oct 21. Oncology. 2016. PMID: 27764830 Free PMC article.
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Subbiah V, et al. JCI Insight. 2017 Apr 20;2(8):e90380. doi: 10.1172/jci.insight.90380. eCollection 2017 Apr 20. JCI Insight. 2017. PMID: 28422758 Free PMC article.
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.
Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Subbiah V, et al. JCO Precis Oncol. 2018 Sep 13;2:PO.18.00189. doi: 10.1200/PO.18.00189. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32913986 Free PMC article.
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Cascone T, et al. Among authors: subbiah im, subbiah v. ESMO Open. 2021 Apr;6(2):100079. doi: 10.1016/j.esmoop.2021.100079. Epub 2021 Mar 12. ESMO Open. 2021. PMID: 33721621 Free PMC article. Clinical Trial.
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Tsimberidou AM, et al. Among authors: subbiah v. NPJ Precis Oncol. 2021 Mar 19;5(1):21. doi: 10.1038/s41698-021-00159-2. NPJ Precis Oncol. 2021. PMID: 33742104 Free PMC article.
580 results